Bluebird Bio | Capitaux D'Emprunt



Capitaux D'Emprunt Changement Date
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 596.66M 501K 2025-09
Gilead Sciences USD 22.14B 5M 2025-09
Incyte USD 35.37M 3.61M 2025-09
Ionis Pharmaceuticals USD 28.78M 596.71M 2025-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Novartis USD 24.24B 174M 2025-09
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 1.84B 298.68M 2025-09
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Sarepta Therapeutics USD 1.04B 104.31M 2025-09
Tectonic Therapeutic USD 100K 86K 2025-09
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03


Bluebird Bio Capitaux D'Emprunt - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.